EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) Given Consensus Recommendation of “Buy” by Analysts

EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company.

A number of research analysts have commented on the company. Zacks Research lowered EssilorLuxottica from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. The Goldman Sachs Group restated a “buy” rating on shares of EssilorLuxottica in a research note on Friday, December 5th. Royal Bank Of Canada reiterated an “outperform” rating on shares of EssilorLuxottica in a research report on Tuesday, October 28th. Citigroup reiterated a “buy” rating on shares of EssilorLuxottica in a research report on Thursday, December 11th. Finally, Barclays began coverage on shares of EssilorLuxottica in a report on Tuesday, September 9th. They set an “overweight” rating on the stock.

EssilorLuxottica Price Performance

OTCMKTS ESLOY opened at $155.90 on Monday. The firm’s fifty day moving average price is $173.61 and its two-hundred day moving average price is $160.55. The company has a quick ratio of 0.67, a current ratio of 0.97 and a debt-to-equity ratio of 0.18. EssilorLuxottica has a 1 year low of $118.18 and a 1 year high of $186.81.

About EssilorLuxottica

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.